scholarly journals High-frequency binge eating predicts weight gain among veterans receiving behavioral weight loss treatments

Obesity ◽  
2014 ◽  
Vol 23 (1) ◽  
pp. 54-61 ◽  
Author(s):  
Robin M. Masheb ◽  
Lesley D. Lutes ◽  
Hyungjin Myra Kim ◽  
Robert G. Holleman ◽  
David E. Goodrich ◽  
...  
Keyword(s):  
Weight Loss ◽  
Weight Gain ◽  
Binge Eating ◽  
High Frequency ◽  
Behavioral Weight Loss ◽  
Weight Loss Treatments

scholarly journals Examining Self-Weighing Behaviors and Associated Features and Treatment Outcomes in Patients with Binge-Eating Disorder and Obesity with and without Food Addiction

Nutrients ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 29
Author(s):  
Ashley A. Wiedemann ◽  
Valentina Ivezaj ◽  
Ralitza Gueorguieva ◽  
Marc N. Potenza ◽  
Carlos M. Grilo
Keyword(s):  
Weight Loss ◽  
Eating Disorder ◽  
Weight Gain ◽  
Binge Eating ◽  
Treatment Outcomes ◽  
Binge Eating Disorder ◽  
Food Addiction ◽  
Behavioral Weight Loss ◽  
Eating Disorder Examination ◽  
Before And After

Food addiction (FA) has been linked to clinical features in binge-eating disorder (BED) and obesity. A feature of behavioral weight loss (BWL) treatment involves frequent weighing. However, little is known regarding how frequency of self-weighing and related perceptions are associated with BWL outcomes among individuals with BED and obesity stratified by FA status. Participants (n = 186) were assessed with the Eating Disorder Examination before and after BWL treatment. Mixed effects models examined FA (presence/absence) before and after (post-treatment and 6- and 12-month follow-up) treatment and associations with frequency of weighing and related perceptions (reactions to weighing, sensitivity to weight gain and shape/weight acceptance). Participants with FA reported more negative reactions to weighing and less acceptance of shape/weight throughout treatment and follow-ups, and both variables were associated with greater disordered eating at follow-ups among participants with FA. Sensitivity to weight gain decreased over time independent of FA status. Frequency of weighing was associated with a greater likelihood of achieving 5% weight loss only among those without FA. Reactions to weighing and sensitivity to weight gain are associated with FA and poorer treatment outcomes in individuals with BED and obesity. Targeting these features may improve BWL outcomes among individuals with BED, obesity and FA.

scholarly journals Binge eating predicts adherence to digital self-monitoring during behavioral weight loss

2020 ◽  
Vol 39 ◽  
pp. 101448
Author(s):  
Mary K. Martinelli ◽  
Laura D'Adamo ◽  
Meghan L. Butryn
Keyword(s):  
Weight Loss ◽  
Binge Eating ◽  
Behavioral Weight Loss ◽  
Self Monitoring

scholarly journals 891. Minimum Manufacturing Costs and National Prices for Weight Loss Treatments, as Potential Mitigation for Anti-Retroviral Related Weight Gain in HIV

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S536-S537
Author(s):  
Jacob Levi ◽  
Junzheng Wang ◽  
Francois Venter ◽  
Andrew Hill
Keyword(s):  
Weight Loss ◽  
Weight Gain ◽  
Export Price ◽  
Minimum Cost ◽  
Hiv Care ◽  
List Price ◽  
Price Data ◽  
Wide Range ◽  
Weight Gains ◽  
Weight Loss Treatments

Abstract Background Weight gain is being observed for a wide range of antiretroviral treatments. Weight gains are higher for people taking first-line integrase inhibitor based treatments, especially those including TAF/FTC. Weight gains are higher for women and people of colour. Clinical obesity increases the risks of cardiovascular disease, diabetes, adverse birth outcomes and could lower survival rates. Anti-obesity treatments are needed to supplement lifestyle interventions and counteract progressive weight gains, but are not routinely provided as part of HIV care. Methods Costs of production for FDA-recommended weight loss treatments and anti-diabetic medications (orlistat, naltrexone-bupropion, topiramate, phentermine, semaglutide, liraglutide and metformin) were estimated using an established and published methodology based on costs of active pharmaceutical ingredients (API), extracted from the global shipping records database Panjiva. This was compared with national drug list price data from a range of low, medium, and high-income countries. Figure 1. Example of methodology for calculating the estimated minimum cost of production for orlistat Results Weight loss and anti-diabetic treatments can be generically manufactured at low per-course costs, e.g. &85 per person per year for oral treatments such as orlistat and &1 per person per month for metformin. However, prices for a year of treatment with orlistat are as high as &1,205 in the USA and as low as &11 in Vietnam. In comparison, a month of ARV treatment costs about &15 via global health institutions like CHAI. Price for injectable (subcutaneous) treatments were higher, ranging from &1,985 for liraglutide in USA to &330 in Morocco, whilst they could potentially be profitably sold for &155 for a 12-week course. No export price data was available for semaglutide. When compared against international list prices, we found wide variations between countries. Table 1. Summary of drug prices and minimum cost estimates Figure 2. Orlistat course costs in a range of countries, compared with estimated minimum cost Figure 3. Liraglutide course costs in a range of countries, compared with estimated minimum cost Conclusion We show that weight loss treatments can be manufactured and sold profitably for low prices, but have a wide price range between countries. Government and non-governmental healthcare systems should be evaluating weight loss agents for inclusion within ART programmes. Disclosures All Authors: No reported disclosures

Some Health-Risk Benefits of Behavioral Weight-Loss Treatments

1987 ◽  
Vol 61 (1) ◽  
pp. 199-206 ◽  
Author(s):  
William M. Beneke ◽  
Benjamin F. Timson
Keyword(s):  
Weight Loss ◽  
Weight Control ◽  
Cardiovascular Health ◽  
Hdl Cholesterol ◽  
Maximal Heart Rate ◽  
Behavioral Weight Loss ◽  
Serum Triglycerides ◽  
Cardiopulmonary Fitness ◽  
Beneficial Effects ◽  
Weight Loss Treatments

This study reports assessment of some beneficial effects of behavioral weight-control treatments on measures of cardiovascular health. 31 women participated for each experiment. In Exp. 1, a 12-wk. dietary program resulted in mean reductions of 5.3 kg of weight, including 4.2 kg of fat, 24% in HDL-cholesterol and 11.95 mg/dl in Total Cholesterol, but no changes in cardiopulmonary fitness. Exp. 2 compared two 16-wk. treatments which added exercise self-management with and without additional structured-group exercise to the dietary component. No differences or interactions between treatments were significant. Combined data showed a mean weight loss of 8.3 kg, including 8.8 kg of fat, a 22% decrease in serum triglycerides, and a 22% increase in duration of exercise combined with a 5% reduction in maximal heart rate. These beneficial effects of including exercise in behavioral weight-loss treatments with women should be experimentally verified.

Comparison of a standard behavioral weight loss treatment and a binge eating weight loss treatment

1995 ◽  
Vol 26 (1) ◽  
pp. 119-134 ◽  
Author(s):  
Linda Krug Porzelius ◽  
Cheryl Houston ◽  
Marcia Smith ◽  
Cynthia Arfken ◽  
Edwin Fisher
Keyword(s):  
Weight Loss ◽  
Binge Eating ◽  
Behavioral Weight Loss ◽  
Weight Loss Treatment ◽  
Behavioral Weight Loss Treatment
Sign in / Sign up

Export Citation Format

Share Document